



## Matthias Preusser

*Austria*

Dr Matthias Preusser is full professor of Medical Oncology and the head of at the Division of Oncology at the Medical University of Vienna, Austria. He serves as Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group and is the Past President of the European Association of Neurooncology (EANO), as well as the Chair of the EANO Guideline Committee. Dr Preusser completed research visits at the German Cancer Research Center (DKFZ, Heidelberg, Germany) and the Memorial Sloan Kettering Cancer Center (New York, USA), is co-author of the current edition of the World Health Organisation (WHO) classification of brain tumors and has published some 450 scientific articles, mainly in the field of interdisciplinary brain tumor research. A focus of his work is on gliomas, meningiomas, and CNS metastases with published translational research, clinical trials and clinical guidelines.

### **Topic: New Advances in Treatment of Breast Cance+P13+P52**

Brain metastases are a common and serious complication of breast cancer, especially in the HER2+ and triple-negative molecular subtypes. While local treatments such as surgery and radiotherapy have long been the mainstay of therapy, systemic pharmacotherapy with novel drugs is emerging as an option. This lecture will discuss the pathobiology and clinical management of breast cancer brain metastases with a focus on recent clinical trials on antibody-drug conjugates and their CNS activity.

### **Topic: Emerging Systemic Treatment Options in Meningioma**

Meningiomas are the most frequently diagnosed intracranial neoplasms. Usually, they are treated by surgical resection in curative intent. Radiotherapy and stereotactic radiosurgery are commonly applied in the adjuvant setting in newly diagnosed atypical (CNS WHO grade 2), and anaplastic (CNS WHO grade 3) meningioma, especially if gross total resection is not feasible, and in recurrent cases. So far, no systemic treatment has been approved for meningioma and there is a lack of high level evidence from clinical trials. This lecture will discuss recent data on pharmacotherapy, as well as theranostic approaches for the treatment of meningiomas.